59
Participants
Start Date
February 19, 2019
Primary Completion Date
January 31, 2030
Study Completion Date
January 31, 2031
Tumor Infiltrating Lymphocytes (TIL)
TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
Udai Kammula
OTHER